Our previous reports revealed the usefulness of investigating the changes in the weight, cellularity, and histology in the spleen caused by alkylating agents to evaluate immunotoxicity, compared with the plaque-forming cell (PFC) assay using appropriate conditions. In this study, dose–response relationships of weight, cellularity, PFC response, and histology in the spleen in rats treated with antimetabolites were studied. A single administration of azathioprine or 6-mercaptopurine (6-MP) caused decreases in spleen weights and cellularity and the PFC response at nearly the same dose level. In the rats treated with these agents for 7 days, spleen weights and cellularity tended to be decreased at doses lower than those suppressing the PFC response. In the rats singly treated with 5-fluorouracil (5-FU), spleen weights and cellularity were decreased at a dose lower than that suppressing the PFC response. At low and middle doses, the PFC response was inversely enhanced by this agent. A 7-day administration of 5-FU caused reductions in spleen weights and cellularity and PFC response at the same dose level. In addition, the spleen in the rats dosed with azathioprine, 6-MP, or 5-FU was histopathologically examined and indicated a dose-related decrease in the size of the spleen without changes in the tissue architecture at doses suppressing the PFC response. On the other hand, in the red pulp, the extramedullary hematopoiesis disappeared by these antimetabolites at the doses. These results indicate that decreases in the weight and cellularity and histological changes in the spleen caused by antimetabolites are detectable at doses suppressing the PFC response.
Asai J, Koshikawa T, Iijima S. (1979) Studies on cellular responses in the perifollicular zone of rat spleen. Recent Advances REC Res19:54–75.
2.
Basketter DA, Bremmer JN, Buckley P, et al. (1995) Pathology considerations for, and subsequent risk assessment of, chemicals identified as immunosuppressive in routine toxicology. Fed Chem Toxic33:239–43.
3.
Braun DP, Harris JE. (1981) Modulation of the immune response by chemotherapy. Pharmac Ther14:89–122.
4.
Calabresi P, Chabner BA. (1990) Chemotherapy of neoplastic diseases. In: Gilman AG, Rall TW, Nies AS, Tayler P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed.New York: Pergamon Press, 1202–76.
5.
Crevel RWR, Buckley P, Robinson JA. (1994) The value of in vitro immune function tests in the detection of potential immunotoxicants. Toxic in Vitro8:1021–5.
6.
Cunningham AJ, Szenberg A. (1968) Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology14:599–601.
7.
Dean JH. (1994) Immunotoxicology: an overview. Toxic in Vitro8:933–7.
8.
Dean JH, Thurmond LM. (1987) Immunotoxicology: an overview. Toxicol Pathol15:265–71.
9.
Descotes J. (1988) Immunotoxicity of immunodepressive and immunoenhancing drugs. In: Immunotoxicology of Drugs and Chemicals.Amsterdam: Elsevier, 234–6.
10.
Descotes J. (1992) Immunosuppression: current strategies. J Toxicol Clin Exp12:421–7.
11.
Descotes J, Vial T, Verdier F. (1993) The how, why and when of immunological testing. Comp Haematol3:63–6.
12.
Doi T, Nakai Y, Yamamoto M, Ando T. (1992) Appropriate conditions for the plaque forming cell (PFC) assay in rats and effects of cyclophosphamide on PFC response. J Toxicol Sci (Japan)17:225–33.
13.
Doi T, Nagai H, Tsukuda R, Suzuki T. (1996) Dose–response relationships of cytotoxicity, PFC response and histology in the spleen in rats treated with alkylating agents. Toxicology104:47–60.
14.
Dunnett CW. (1955) A multiple comparison procedure for comparing several treatments with a control. J Am Statist Assoc50:1096–129.
15.
Exon JH, Koller LD, Talcott PA, O'Reilly CA, Henningsen GM. (1986) Immunotoxicity testing: an economical multiple-assay approach. Fund Appl Toxicol7:387–97.
16.
Fautz R, Miltenburger HG. (1993) Immunotoxicity screening in vitro using an economical multiple endpoint approach. Toxic in Vitro7:305–10.
17.
Fouhil AFIE, Iskander FA, Turkall RM. (1993) Effect of alternate-day hydrocortisone therapy on the immunologically immature rat. II: Changes in T- and B-cell area in spleen. Toxicol Pathol21:383–90.
18.
Goldschneider I, McGregor DD. (1973) Anatomical distribution of T and B lymphocytes in rat development of lymphocyte-specific antisera. J Exp Med138:1443–65.
19.
Greaves P, Faccini JM. (1992) Haemopoietic and lymphatic systems. In: Rat Histopathology: A Glossary for Use in Toxicity and Carcinogenicity Studies.Amsterdam: Elsevier, 35–56.
20.
Haskell CM. (1977) Immunologic aspects of cancer chemotherapy. Ann Rev Pharmacol Toxicol17:179–95.
21.
Heppner GH, Calabresi P. (1976) Selective suppression of humoral immunity by antineoplastic drugs. Ann Rev Pharm Toxicol16:367–79.
22.
Kempf RA, Mitchell MS. (1984) Effects of chemotherapeutic agents on the immune response. I. Cancer Invest2:459–66.
23.
Kempf RA, Mitchell MS. (1985) Effects of chemotherapeutic agents on the immune response. II. Cancer Invest3:23–33.
24.
Kim Z. (1981) Immunosuppression and chemotherapeutic agents. Ann Allergy47:78–83.
25.
Kimball AP, Herriot SJ, Allinson PS. (1967) Studies on immune suppressive drugs. Proc Soc Exp Biol Med126:181–4.
26.
Kociba RJ. (1981) Morphologic considerations in the detection of immune suppression in routine toxicity studies. In: Sharma RP, ed. Immunologic Considerations in Toxicology (chapter 6). Boca Raton, FL: CRC Press Inc, 123–31.
27.
Kruskal WH, Wallis WA. (1952) Use of ranks in one-criterion variance analysis. J Am Statist Assoc47:583–621.
28.
Kumararatne DS, Bazin H, MacLennan ICM. (1981) Marginal zones: the major B cell compartment of rat spleens. Eur J Immunol11:858–64.
29.
Ladics GS, Smith C, Heaps K, Elliott GS, Slone TW, Loveless SE. (1995) Possible incorporation of an immunotoxicological functional assay for assessing humoral immunity for hazard identification purposes in rats on standard toxicology study. Toxicology96:225–38.
30.
Lebrec H, Roger R, Blot C, Burleson GR, Bohuon C, Pallardy M. (1995) Immunotoxicological investigation using pharmaceutical drugs. In vitro evaluation of immune effects using rodent or human immune cells. Toxicology96:147–56.
31.
Lin H. (1973) Differential lethal effect of cytotoxic agents on proliferating and nonproliferating lymphoid cells. Cancer Res33:1716–20.
32.
Lin H. (1976) Schedule-dependent effect of phase-specific cytotoxic agents on production of hemolytic plaque-forming cells. J Nat Cancer Inst56:95–9.
33.
Luster MI, Munson AE, Thomas PT, et al. (1988) Methods evaluation: development of a testing battery to assess chemical-induced immunotoxicity: national toxicology program's guidelines for immunotoxicity evaluation in mice. Fund Appl Toxicol10:2–19.
34.
Luster MI, Portier C, Pait DG, et al. (1992) Risk assessment in immunotoxicity I. Sensitivity and predictability of immune tests. Fund Appl Toxicol18:200–10.
35.
Luster MI, Portier C, Pait DG, et al. (1993) Risk assessment in immunotoxicology II. Relationships between immune and host resistance tests. Fund Appl Toxicol21:71–82.
Matsumoto K, Sekita K, Ochiai T, et al. (1990) Evaluation of immunotoxicity testings using azathioprine-treated rats: the international collaborative immunotoxicity study (azathioprine). Bull Natl Inst Hyg Sci (Japan)108:34–9.
38.
Meredith C, Miller K. (1994) Molecular immunotoxicology testing in vitro. Toxic in Vitro8:1001–5.
39.
Merritt K, Johnson AG. (1963) Studies on the adjuvant action of bacterial endotoxins on antibody formation. V. The influence of endotoxin and 5-fluoro-2-deoxyuridine on the primary antibody response of the BALB mouse to a purified protein antigen. J Immunol91:266–72.
40.
Miller K. (1985) Review immunotoxicology. Clin Exp Immunol61:219–23.
41.
Miller K. (1992) In vitro immunotoxicology. J Toxicol Clin Exp12:455–60.
42.
Mitchell MS, DeConti RC. (1970) Immunosuppression by 5-fluorouracil. Cancer26:884–9.
43.
Munson AE, White Jr KL. (1990) Immunotoxicology. In: Clayson DB, Munro IC, Shubik P, Swenberg JA, eds. Progress in Predictive Toxicology.Amseterdam: Elsevier, 285–313.
44.
Panajotovova V, Melka M. (1991) Effect of new purine analog 6-purinyl-N-[2-chloroethyl]-thiocarbamate (cloturin) on immune system of mice. Neoplasma38:565–74.
45.
Remandet B. (1992) Immunotoxicology and conventional toxicology. J Toxicol Clin Exp12:397–403.
46.
Saijo T, Miyajima H. (1995) Present status and problems with the methods for testing immunotoxicity. J Toxicol Pathol (Japan)8:245–56.
47.
Santos GW, Owens Jr AH, Sensenbrenner LL. (1964) Effects of selected cytotoxic agents on antibody production in man: a preliminary report. Ann NY Acad Sci114:404–23.
48.
Santos GW. (1967) Immunosuppressive drugs. I. Fed Proc26:907–13.
49.
Schuurman H-J, Krajnc-Franken MAM, Kuper CF, van Loveren H, Vos JG. (1991) Immune system. In: Haschek WM, Rousseaux CG, eds. Handbook of Toxicologic Pathology.San Diego: Academic Press, Inc., 421–87.
50.
Schuurman H-J, Kuper CF, Vos JG. (1994) Histopathology of the immune system as a tool to assess immunotoxicity. Toxicology86:187–212.
51.
Schwartz R, Stack J, Dameshek W. (1958) Effect of 6-mercaptopurine on antibody production. Proc Soc Exp Biol Med99:164–7.
52.
Schwartz RS. (1966) Specificity of immunosuppression by antimetabolites. Fed Proc125:165–8.
53.
Snedecor GW, Cochran WG. (1980) Statistical Methods, 7th ed.Ames, Iowa: Iowa State University Press.
54.
Spina CA. (1984) Azathioprine as an immune modulating drug: clinical applications. Clin Immunol Allergy4:415–46.
55.
Stockman GD, Heim LR, South MA, Trentin JJ. (1973) Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol110:277–82.
56.
Tukey JW, Ciminera JL, Heyse JF. (1985) The consultant's forum: testing the statistical certainty of a response to increasing doses of a drug. Biometrics41:295–301.
57.
Turk JL, Poulter LW. (1972) Selective depletion of lymphoid tissue by cyclophosphamide. Clin Exp Immunol10:285–96.
58.
Turk JL, Parker D. (1982) Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev65:99–113.
59.
Uyeki EM. (1967) Effects of several antitumor agents on spleen hemolysin plaque-forming cells. Biochem Pharmacol16:53–8.
60.
Uyeki EM, Long J. (1967) Antitumor agents on the production of primary and secondary spleen hemolysin plaque-forming cells. J Pharmacol Exp Ther158:365–71.
61.
van Krieken JHJM, te Velde J. (1992) Spleen. In: Sternberg SS, ed. Histology for Pathologists.New York: Raven Press, 253–60.
62.
Verdier F. (1992) Specific methods to evaluate the immune system: functional assays. J Toxicol Clin Exp12:405–19.
63.
Vos JG. (1977) Immune suppression as related to toxicology. CRC Crit Rev Toxicol5:67–101.
64.
Vos JG, van Loveren H. (1987) Immunotoxicity testing in the rat. Adv Mod Environ Toxicol13:167–80.
65.
Winkelstein A. (1984) Immune suppression resulting from various cytotoxic agents. Clin Immunol Allergy4:295–315.
